AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17828086 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinuforte monotherapy in a single daily dose for 7 days
Number of subjects: 120
Study 17828086 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for 7 days
Number of subjects: 120
Study 15173403 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy) for 3 weeks
Number of subjects: 2
Study 15173403 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (29% of energy) for 3 weeks
Number of subjects: 2
Study 10828731 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of nicotine polacrilex
Number of subjects: 13
Study 10828731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9115804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice by practice nurses
Number of subjects: 956
Study 9115804 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard health education materials)
Number of subjects: 956
Study 8478502 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose maintenance treatment
Number of subjects: 0
Study 8478502 — intervention group
Group type: COMPARATOR
Intervention: Half-dose maintenance treatment
Number of subjects: 0
Study 8478502 — intervention group
Group type: COMPARATOR
Intervention: Full-dose vs Half-dose
Number of subjects: 0
Study 3538178 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Care (SC)
Number of subjects: 10940
Study 3538178 — intervention group
Group type: COMPARATOR
Intervention: Research Care (RC)
Number of subjects: 10940
Study 3538178 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of persons with DBP 90 to 104 mm Hg
Number of subjects: 10940
Study 31471827 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoy option (two appointments: one with a male endoscopist and one with a female endoscopist)
Number of subjects: 602
Study 31471827 — intervention group
Group type: COMPARATOR
Intervention: Control (appointment with a female endoscopist)
Number of subjects: 602
Study 30232974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based short message services (SMSs) delivered for 12 months, tailored to recent FBG values.
Number of subjects: 955
Study 30232974 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS intervention).
Number of subjects: 955
Study 30232974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group compared to control group, adjusted for baseline FBG.
Number of subjects: 955
Study 27711089 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of serenoa repens, selenium and lycopene extract + bromelain and methylsulfonylmethane extract with levofloxacin 500 mg o.d. for 14 days (Group A)
Number of subjects: 79
Study 27711089 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg o.d. for 14 days only (Group B)
Number of subjects: 79
Study 27711089 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of serenoa repens, selenium, lycopene + bromelain and methylsulfonylmethane extracts with levofloxacin (Group A)
Number of subjects: 79
Study 27711089 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin only (Group B)
Number of subjects: 79
Study 24909532 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad practice
Number of subjects: 36
Study 24909532 — intervention group
Group type: COMPARATOR
Intervention: Individual practice
Number of subjects: 36
Study 22258155 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RST)
Number of subjects: 41
Study 22258155 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (PT)
Number of subjects: 41
Study 20146022 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived discrimination
Number of subjects: 36831
Study 18981773 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 PCR testing at 4-8 weeks followed by a second test at 1 month after weaning or at 1 year of age
Number of subjects: 1609
Study 16188750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (four group sessions)
Number of subjects: 60
Study 16188750 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 16188750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 60
Study 12431356 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HB/Hib pentavalent combination vaccine
Number of subjects: 207
Study 12431356 — intervention group
Group type: COMPARATOR
Intervention: DTPw-HB vaccine alone
Number of subjects: 207
Study 12431356 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HB/Hib pentavalent vaccine
Number of subjects: 207
Study 12431356 — intervention group
Group type: COMPARATOR
Intervention: DTPw/Hib vaccine
Number of subjects: 207
Study 9867443 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (glucose, insulin, and potassium infusion)
Number of subjects: 407
Study 9867443 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 407
Study 7872278 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg t.i.d. azithromycin, tetracycline 500 mg q.i.d., bismuth subsalicylate 2 tablets q.i.d.
Number of subjects: 30
Study 7872278 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg b.i.d. azithromycin, tetracycline 500 mg q.i.d., bismuth subsalicylate 2 tablets q.i.d.
Number of subjects: 30
Study 7872278 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg t.i.d. azithromycin, tetracycline 500 mg q.i.d., bismuth subsalicylate 2 tablets q.i.d. with ranitidine 300 mg
Number of subjects: 30
Study 2129025 — intervention group
Group type: EXPERIMENTAL
Intervention: gliclazide
Number of subjects: 248
Study 2129025 — intervention group
Group type: EXPERIMENTAL
Intervention: glibenclamide
Number of subjects: 248
Study 2129025 — intervention group
Group type: EXPERIMENTAL
Intervention: glipizide
Number of subjects: 248
Study 113370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream containing 5‐chloro‐8‐hydroxyquinoline, gentamycin and fluprednyliden‐21‐acetate
Number of subjects: 60
Study 113370 — intervention group
Group type: COMPARATOR
Intervention: Cream containing 5‐chloro‐8‐hydroxyquinoline and gentamycin alone
Number of subjects: 60
Study 30888221 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Training Group (ATG)
Number of subjects: 34
Study 30888221 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training Group (RTG)
Number of subjects: 34
Study 29397376 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 0·5 mg
Number of subjects: 1201
Study 29397376 — intervention group
Group type: COMPARATOR
Intervention: dulaglutide 0·75 mg
Number of subjects: 1201
Study 29397376 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 1·0 mg
Number of subjects: 1201
Study 29397376 — intervention group
Group type: COMPARATOR
Intervention: dulaglutide 1·5 mg
Number of subjects: 1201
Study 27055505 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA, TACE, CIK
Number of subjects: 156
Study 27055505 — intervention group
Group type: COMPARATOR
Intervention: RFA, TACE
Number of subjects: 156
Study 24413350 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise training (HIT) - 3 hospital-based exercise sessions per week for 4 weeks, including 2 or 4 min of high-intensity stationary cycling followed by the same duration of easy cycling or passive recovery, repeated until a total of 16 min of high-intensity exercise is accumulated.
Number of subjects: 50
Study 24413350 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 50
Study 24413350 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative outcomes
Number of subjects: 50
Study 24413350 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment 12 weeks post-discharge
Number of subjects: 50
Study 24413350 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs associated with the exercise intervention and healthcare utilisation
Number of subjects: 50
Study 21833738 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable partly resorbable calcium sulfate (60 wt.%)/hydroxyapatite (40 wt.%) bone substitute
Number of subjects: 80
Study 20849856 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg oral 17‐β estradiol
Number of subjects: 20
Study 20849856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17351252 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of BE500P
Number of subjects: 257
Study 17351252 — intervention group
Group type: COMPARATOR
Intervention: 4 cycles of E500P
Number of subjects: 257
Study 15765238 — intervention group
Group type: EXPERIMENTAL
Intervention: Living high-training low (LHTL) at simulated altitudes of 2,500, 3,000, and 3,500 m for 18 days
Number of subjects: 11
Study 15765238 — intervention group
Group type: COMPARATOR
Intervention: Control group training and living at 1,200 m altitude
Number of subjects: 11
Study 12478899 — intervention group
Group type: EXPERIMENTAL
Intervention: L-OHP plus HCPT
Number of subjects: 43
Study 12478899 — intervention group
Group type: COMPARATOR
Intervention: VP-16 + CF + 5-FU (ELF)
Number of subjects: 43
Study 9718224 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific agents not detailed, but cyclophosphamide noted as most mutagenic)
Number of subjects: 9
Study 9718224 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 9
Study 7917158 — intervention group
Group type: EXPERIMENTAL
Intervention: quinapril
Number of subjects: 10
Study 7917158 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 10
Study 7917158 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 10
Study 7917158 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 2680226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) administration in high UAER group
Number of subjects: 0
Study 2680226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) administration in low UAER group
Number of subjects: 0
Study 2680226 — intervention group
Group type: COMPARATOR
Intervention: Placebo in high UAER group
Number of subjects: 0
Study 2680226 — intervention group
Group type: COMPARATOR
Intervention: Placebo in low UAER group
Number of subjects: 0
Study 1112230 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titre rubella immunoglobulin administered intramuscularly (20 ml)
Number of subjects: 56
Study 1112230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunoglobulin)
Number of subjects: 56
Study 7197091 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (gestagen therapy)
Number of subjects: 300
Study 7197091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 31792258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PEG‐LG) 40 mg/m2 plus cyclophosphamide (CPM) 600 mg/m2 followed by docetaxel (DTX) 85 mg/m2, administered in four cycles on a 21-day schedule.
Number of subjects: 0
Study 31792258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PEG‐LG) plus cyclophosphamide (CPM) followed by docetaxel (DTX) regimen.
Number of subjects: 0
Study 29492878 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasiglifam
Number of subjects: 9139
Study 29492878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9139
Study 29492878 — intervention group
Group type: COMPARATOR
Intervention: Active Comparators (sitagliptin, glimepiride)
Number of subjects: 9139
Study 27445610 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasternal block
Number of subjects: 120
Study 27445610 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 120
Study 27445610 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 25002083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propacetamol (1g IV dose)
Number of subjects: 0
Study 25002083 — intervention group
Group type: COMPARATOR
Intervention: Oral rizatriptan (5mg)
Number of subjects: 0
Study 22542122 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine therapy (4-8 mg daily)
Number of subjects: 645
Study 22542122 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 645
Study 19054247 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic group (RFA catheter selection based on CTI angiography)
Number of subjects: 119
Study 19054247 — intervention group
Group type: COMPARATOR
Intervention: Externally cooled-tip catheter group
Number of subjects: 119
Study 17993029 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips
Number of subjects: 87
Study 17993029 — intervention group
Group type: EXPERIMENTAL
Intervention: 18% carbamide peroxide whitening gel
Number of subjects: 87
Study 17993029 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fluoride toothpaste)
Number of subjects: 87
Study 15679130 — intervention group
Group type: COMPARATOR
Intervention: etomidate 0.3 mg/kg
Number of subjects: 60
Study 15679130 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 2 microg/kg and etomidate 0.3 mg/kg
Number of subjects: 60
Study 15679130 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine 1 mg/kg and etomidate 0.3 mg/kg
Number of subjects: 60
Study 12032266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen (colestipol 5 g/d with pravastatin 10 mg/d)
Number of subjects: 36
Study 12032266 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen (colestipol 10 g/d)
Number of subjects: 36
Study 12032266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 36
Study 9650540 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine therapy at 11 mg/day
Number of subjects: 70
Study 9650540 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine therapy at 22 mg/day
Number of subjects: 70
Study 9650540 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine therapy at 44 mg/day
Number of subjects: 70
Study 7714284 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care with a focus on emotional support
Number of subjects: 26
Study 7714284 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational changes in care (co-operation between surgical ward and primary health care, shorter waiting times, changed routines around information)
Number of subjects: 26
Study 2716711 — intervention group
Group type: EXPERIMENTAL
Intervention: Jatrox (three times 2 tablets one hour before meals)
Number of subjects: 15
Study 2716711 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 15
Study 1009064 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 degrees scatter xenon photocoagulation
Number of subjects: 20
Study 1009064 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 20
Study 31859593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive biases (conjunction fallacy, sunk cost bias, information avoidance, present bias)
Number of subjects: 1400
Study 31859593 — intervention group
Group type: EXPERIMENTAL
Intervention: Information avoidance
Number of subjects: 1400
Study 29908682 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g Melissa officinalis (MO) supplement daily for 8 weeks
Number of subjects: 80
Study 29908682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26855550 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI with 0.3% ropivacaine
Number of subjects: 75
Study 26855550 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 0.12% ropivacaine and 20 µg/mL morphine
Number of subjects: 75
Study 26855550 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia with 0.5 mg/mL morphine
Number of subjects: 75
Study 24988100 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness intervention (n = 44)
Number of subjects: 89
Study 24988100 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n = 45)
Number of subjects: 89
Study 22634446 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 µg or 25 µg VLP immunotherapy
Number of subjects: 85
Study 22634446 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg VLP immunotherapy
Number of subjects: 85
Study 22634446 — intervention group
Group type: COMPARATOR
Intervention: Placebo immunotherapy (0.9% NaCl)
Number of subjects: 85
Study 22634446 — intervention group
Group type: COMPARATOR
Intervention: Placebo immunotherapy (0.9% NaCl) in Wenzhou
Number of subjects: 85
Study 22634446 — intervention group
Group type: EXPERIMENTAL
Intervention: VLP immunotherapy in Wenzhou
Number of subjects: 85
Study 19895362 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with birch pollen allergen extract
Number of subjects: 24
Study 18565093 — intervention group
Group type: EXPERIMENTAL
Intervention: Menicon PremiO lenses
Number of subjects: 0
Study 18565093 — intervention group
Group type: COMPARATOR
Intervention: Acuvue Oasys lenses
Number of subjects: 0
Study 18565093 — intervention group
Group type: EXPERIMENTAL
Intervention: All lens/solution combinations
Number of subjects: 0
Study 15882248 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy (Lactobacillus rhamnosus GG, L. rhamnosus LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp. shermanii JS) during H. pylori eradication and for 3 weeks following treatment.
Number of subjects: 47
Study 15882248 — intervention group
Group type: COMPARATOR
Intervention: Placebo during H. pylori eradication and for 3 weeks following treatment.
Number of subjects: 47
Study 15882248 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy
Number of subjects: 47
Study 15882248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 14659474 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (6 mg/kg in mice, 10 mg/kg in rats)
Number of subjects: 0
Study 14659474 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (3 mg/kg)
Number of subjects: 0
Study 14659474 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg/kg)
Number of subjects: 0
Study 14659474 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (not specified dosage)
Number of subjects: 0
Study 14659474 — intervention group
Group type: COMPARATOR
Intervention: Chronic buspirone treatment (3 x 10 mg daily for 6 weeks)
Number of subjects: 0
Study 14659474 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from nonrelatives
Number of subjects: 0
Study 10833209 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (somatropin) - loading dose of 5 mg per day subcutaneously for one week, followed by a maintenance dose of 1.5 mg per day
Number of subjects: 37
Study 10833209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 8834888 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin (400 mg, single dose)
Number of subjects: 203
Study 8834888 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (400 mg twice a day for 3 days)
Number of subjects: 203
Study 1557681 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention combined with individual treatment
Number of subjects: 75
Study 1557681 — intervention group
Group type: COMPARATOR
Intervention: Individual treatment alone
Number of subjects: 75
Study 3891615 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (n = 10) with maintained urinary sodium excretion at predieting level
Number of subjects: 18
Study 3891615 — intervention group
Group type: COMPARATOR
Intervention: Group II (n = 8) with restricted energy and sodium intake
Number of subjects: 18
Study 30148453 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approach
Number of subjects: 0
Study 30148453 — intervention group
Group type: COMPARATOR
Intervention: Traditional null hypothesis significance testing
Number of subjects: 0
Study 27050325 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (one-hour twice-weekly sessions for at least three and a maximum of four weeks prior to surgery)
Number of subjects: 64
Study 27050325 — intervention group
Group type: COMPARATOR
Intervention: Control (no pre-surgical programs)
Number of subjects: 64
Study 24885096 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling protocol with the It's LiFe! tool (group 1)
Number of subjects: 240
Study 24885096 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling protocol without the It's LiFe! tool (group 2)
Number of subjects: 240
Study 24885096 — intervention group
Group type: COMPARATOR
Intervention: Usual care (group 3)
Number of subjects: 240
Study 22450480 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cognitive assessment after carotid endarterectomy (CEA)
Number of subjects: 213
Study 22450480 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing before and after surgery
Number of subjects: 213
Study 22450480 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for neuropsychological test scores
Number of subjects: 213
Study 22450480 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological test scores exceeding cut-off points
Number of subjects: 213
Study 19903661 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg o.d. and Candesartan 16 mg o.d. (combined treatment)
Number of subjects: 47
Study 22433042 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (5 g 4/day for days 1-7; 2.5 g 2/day for days 8-14)
Number of subjects: 11
Study 22433042 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 11
Study 15654537 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination in 2002/2003 season
Number of subjects: 4011
Study 15654537 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination in 2003/2004 season
Number of subjects: 4011
Study 15654537 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for being vaccinated
Number of subjects: 4011
Study 15654537 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for not being vaccinated
Number of subjects: 4011
Study 15654537 — intervention group
Group type: EXPERIMENTAL
Intervention: Options encouraging vaccination
Number of subjects: 4011
Study 12460817 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional cleaning of homes
Number of subjects: 765
Study 12460817 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional cleaning of homes (for homes with precleaning dust lead levels above recommended clearance levels)
Number of subjects: 765